Search results
Biomed 2024 Showcases Israel’s Resilient Entrepreneurial Spirit
Forbes· 5 days agoThe need to defend Israeli citizens on multiple fronts for more than seven months has not depressed...
ASCO: With hopes high, Regeneron misses mark with just 1 complete response in solid tumor trial so...
FierceBiotech· 1 day agoRegeneron’s costimulatory bispecific antibody REGN7075 is being tested in patients with advanced...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 23 hours agoSALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and its collaborators will share data from seven studies at the 2024 ASCO Annual Meeting. Three studies
Butler County resident fighting to keep Verizon from installing cell phone tower near property
CBS News· 4 days agoWe're seeing more and more cell phone towers pop up, but what if one's planned for directly across...
The 10 Healthiest Low-Sugar Fruits You Can Eat
Eat This, Not That! via AOL· 6 days agoShutterstockIf you're concerned about your sugar intake, it's not without merit—after all, most Americans consume too much sugar. The average U.S....
Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial
FOX 23 News Albany· 3 days ago("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that treatment has commenced ...
BioNTech (NASDAQ:BNTX) Shares Up 6.1%
ETF DAILY NEWS· 11 hours agoBioNTech SE (NASDAQ:BNTX – Get Free Report) shares shot up 6.1% during trading on Wednesday . 657,251 shares were traded during mid-day trading, an increase of 4% from the average session volume ...
ValiRx (LON:VAL) Stock Price Down 10%
ETF DAILY NEWS· 2 days agoShares of ValiRx plc (LON:VAL – Get Free Report) dropped 10% on Tuesday . The company traded as low as GBX 3.55 ($0.05) and last traded at GBX 3.60 ($0.05). Approximately 9,956,905 shares changed ...
23andMe (ME) Q4 FY24 Earnings: Revenue Beats Estimates Despite 3
Guru Focus· 1 day agoRevenue: $64 million for Q4 FY24, exceeding analyst estimates of $55.82 million and down 31% year-over-year from $92.4 million.Annual Revenue: $219.6 million f
A genome-wide association study identifies a locus associated with knee extension strength in older...
Nature· 5 days agoA genome-wide association study on knee extension strength in 3452 persons of Japanese ancestry 60 years old and above identifies a significant association at a single locus that includes TACC2, a gene encoding a cytoskeleton-related protein.
